<DOC>
	<DOC>NCT02171429</DOC>
	<brief_summary>This phase III, double blind, placebo and active comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active UC who are na√Øve to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.</brief_summary>
	<brief_title>A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of UC established at least 6 months prior to randomization Moderately to severely active UC as determined by the MCS Naive to treatment with any antiTNF therapy An inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment Background UC therapy may include oral 5aminosalisylate (ASA), oral corticosteroids, budesonide multimatrix system (MMX), probiotics, azathioprine (AZA), 6mercaptopurine (MP), or methotrexate (MTX) if doses have been stable for the 8 weeks immediately prior to randomization Use of highly effective contraception method as defined by the protocol Have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, stricture (stenosis) of the colon, toxic megacolon, or unremoved adenomatous colonic polyps Prior or planned surgery for UC Past or present ileostomy or colostomy Have received nonpermitted inflammatory bowel disease (IBD) antiintegrin therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol Congenital or acquired immune deficiency, chronic hepatitis B or C infection, HIV positive Evidence of or treatment for Clostridium difficile within 60 days prior to randomization or other intestinal pathogens within 30 days prior to randomization History of active or latent tuberculosis (TB), recurrent opportunistic infections, severe disseminated viral infections and organ transplant Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening Received a live attenuated vaccine within 4 weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>